MA-BRIGHTCOVE
Brightcove (NASDAQ: BCOV), the world’s most trusted streaming technology company, today announced Sistema Brasileiro de Televisão (SBT), one of Brazil's most prominent TV networks, has chosen Brightcove as its official streaming technology partner to power its new AVOD app, +SBT. The service is scheduled to launch in April. Selected for its Emmy Award-winning technology, Brightcove’s reliability, scalability, and security will help SBT stream content from its more than 100 broadcast stations directly to audiences throughout Brazil.
“SBT is one of the most well-known media organizations in Brazil. The launch of their new streaming service will be a significant step for the company and its viewers and a great example of how entertainment and content can merge with technology to reach bigger audiences,” said Marc DeBevoise, CEO of Brightcove. “Today’s consumers demand instant access to news and content, making streaming an integral part of any media organization’s strategy. By partnering with us, SBT will be able to provide a seamless in-app streaming experience to expand their reach with new audiences, deepen engagement, and further monetize their content.”
Brightcove’s work with SBT underlines the importance of having a trusted technology partner in the media and streaming industry. Consumer demand for high-quality streams continues to rise, and media companies are increasingly recognizing the need to partner with scalable and reliable technology leaders who can deliver superior and cost-effective solutions, tailored to grow their streaming businesses, revenue, and end-user experiences.
“As one of the most-watched TV networks in Brazil, we needed to find a reliable way to deliver a wide range of video content to our viewers, including popular TV shows, news programs, and events,” said Roberto Grosman, Chief Transformation Officer at SBT. “We found a valuable partner in Brightcove. With their robust streaming solutions, we can trust that our audiences will be able to consume high-quality and secure video streams. We’ll also be able to view first-party data analytics to adapt our content and streaming strategy accordingly.”
SBT joins a roster of media companies that rely on Brightcove to power their streaming capabilities, including AMC Networks, BBC Studios, Forbes, In the Black Network, NHL, SKY Mexico, The Academy of Motion Pictures and Sciences, The National Academy of Television Arts & Sciences, and Yahoo.
For more information, visit Brightcove.com.
About Sistema Brasileiro de Televisão (SBT)
On August 19, 1981, the Sistema Brasileiro de Televisão was inaugurated. Considered the Brazilian family channel, SBT reaches 200 million viewers and 69 million homes. It currently has 114 stations across the country, with 24 hours of diversified programming, with a share of 9.4% in Greater São Paulo and 8.4% in Brazil. The SBT complex has a total area of 230,000m² with 74,000m² of built area. It has eight studios, totaling an area of more than 4,400 m², and a scenographic city of 6,500 m². SBT is a consolidated success in auditorium programs, a reference in the production of content for children and young people. It has impartial and credible journalism, in addition to a strong digital presence with exclusive content.
Source: Kantar IBOPE Media - Instar Analytics - Household Data - SHR% Total Connected - Greater São Paulo and Metropolitan Regions (15 markets) - 24 hours - Jan to Jul/22 | SBT Coverage Atlas – Jul/22. |
About Brightcove, Inc.
Brightcove creates the world’s most reliable, scalable, and secure streaming technology solutions to build a greater connection between companies and their audiences, no matter where they are or on which devices they consume content. In more than 60 countries, Brightcove’s intelligent video platform enables businesses to sell to customers more effectively, media leaders to stream and monetize content more reliably, and every organization to communicate with team members more powerfully. With two Technology and Engineering Emmy® Awards for innovation, uptime that consistently leads the industry, and unmatched scalability, we continuously push the boundaries of what video can do. Follow Brightcove on LinkedIn, X (Formerly Twitter), Facebook, Instagram, Threads, and YouTube. Visit Brightcove.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240207031743/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global forstærker sin dækning af Asien-Stillehavsregionen med ejendomsrådgivere i Australien13.12.2024 19:39:00 CET | Pressemeddelelse
Andersen Global styrker sin platform i Asien og Stillehavsregionen gennem en samarbejdsaftale med Charter Keck Cramer, der er et af Australiens førende, uafhængige ejendomsrådgivningsfirmaer. Det, der i 1970 begyndte som en lille virksomhed, Charter Keck Cramer, har siden udviklet sig til et tværfagligt firma med mere end 170 eksperter, der er fordelt på fem kontorer i Australien og Singapore. Firmaet tilbyder et omfattende udvalg af ejendomsrelaterede ydelser, herunder værdiansættelser inden for bolig- og erhvervsejendomme, ejendoms- og udviklingsrådgivning, ejendomsdata og analyser samt strategisk planlægning og byøkonomi samt kvantitetsopmåling. Charter Keck Cramer betjener en mangfoldig australsk og international kundebase, herunder offentlige og private virksomheder, ejere og udviklere, større banker og finansielle institutioner, institutionelle ejere og truster, statslige organer og familiekontorer. "Vores vækst over de seneste 54 år er drevet af vores uafhængige, skræddersyede t
Experian’s 2024 Global Identity & Fraud Report Spotlights Huge Growth in Highly Personalized GenAI-Driven Fraud Attacks13.12.2024 15:00:00 CET | Press release
Businesses Must Employ a Multi-Layered Approach to Fight GenAI Fraud Today, Experian announced its 2024 Global Identity & Fraud Report that provides a comprehensive view of the consumer and business response to the latest fraud patterns and fraud‑mitigation strategies in the worldwide financial services sector. The report offers combined insights from more than 1,000 businesses and fraud leaders globally, as well as 4,000 consumers, focusing on fraud management and the digital experience. Among its key insights, the report casts a bright spotlight on three factors driving the fast-evolving fraud landscape: the huge growth in Generative Artificial Intelligence (GenAI) technologies, changing government regulations, and the push among businesses to provide consumers with secure and convenient digital experiences. In response to these factors, the report’s findings revealed that businesses intend to increase fraud budgets driven by investments in AI and machine learning technologies. “Unli
Capcom Announces Onimusha Way of the Sword, Marking the First New Title in the Series in Over 20 Years! Work on an Okami Sequel Project Begins!13.12.2024 14:00:00 CET | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that Onimusha Way of the Sword, the first new title in the Onimusha series in over 20 years, is scheduled to be released, while work on an Okami sequel project has also started. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213232085/en/ Onimusha Way of the Sword (Graphic: Business Wire) The Onimusha series consists of swordplay action games where players assume the role of warriors with the superhuman powers of the Oni and fight against monsters bent on world domination. Onimusha Way of the Sword, scheduled to be released globally in 2026, is a Japanese-inspired dark fantasy game set at the beginning of the Edo period in Kyoto, which has been eerily transformed by clouds of Malice. In the game, the samurai protagonist is equipped with the Oni Gauntlet and engages in epic sword battles with the grotesque and otherworldly creatures known as Genma. Capcom hopes that players loo
BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell13.12.2024 13:51:00 CET | Press release
BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and Cellistic, a leader in advanced iPS cell therapy manufacturing, today announced a process development and manufacturing agreement to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials. The strategic collaboration includes the use of Cellistic's innovative 3D bioreactor-based manufacturing platform, Echo, to enable GMP-compliant, clinical-scale manufacturing of iPSC-derived BCMA-targeting CAR-NKT cells for Phase 1 multiple myeloma trial; establishing BrightPath as a first mover in this emerging field. “The use of NKT cells as effectors in allogeneic CAR-T therapy represents a promising strategy, offering not only direct cytotoxicity but also indirect anti-tumor activity through the priming of host CD8+ T cells—a mechanism expected to evade host immune rejection and to enhance the dur
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union13.12.2024 07:00:00 CET | Press release
Atopic dermatitis is a common, chronic, and flaring inflammatory skin disease characterized by persistent itch and recurrent skin lesions, and affects approximately up to 40 million people in the European Union (EU)1-4 Prurigo nodularis is a serious skin disease characterized by chronic itch, skin nodules covering large body areas, and poor sleep quality, which is estimated to affect up to 111 people per 100,000 in the EU5-10 Nemolizumab is a first-in-class monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31.2 IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation and skin barrier dysfunction in both atopic dermatitis and prurigo nodularis11-13 This positive opinion from the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) recommending the granting of marketing authorization of nemolizumab in the European Union (EU) for the treatment of both atopic dermatitis and prurigo n
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom